Evidence map›Paper›PMID 27450538›Full record

ArticleBMC infectious diseases2016

Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.

Francesco Nicoli, Mkunde Chachage, Petra Clowes, Asli Bauer, Dickens Kowour, Barbara Ensoli, Aurelio Cafaro, Leonard Maboko, Michael Hoelscher, Riccardo Gavioli and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Francesco NicoliCenter for International Health, Ludwig-Maximilians-Universität München, Leopoldstraße 7, 80802, Munich, Germany. nclfnc1@unife.it.
Mkunde ChachageCenter for International Health, Ludwig-Maximilians-Universität München, Leopoldstraße 7, 80802, Munich, Germany.
Petra ClowesNational Institute for Medical Research (NIMR)-Mbeya Medical Research Centre, Mbeya, Tanzania.
Asli BauerNational Institute for Medical Research (NIMR)-Mbeya Medical Research Centre, Mbeya, Tanzania.
Dickens KowourNational Institute for Medical Research (NIMR)-Mbeya Medical Research Centre, Mbeya, Tanzania.
Barbara EnsoliNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Aurelio CafaroNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Leonard MabokoNational Institute for Medical Research (NIMR)-Mbeya Medical Research Centre, Mbeya, Tanzania.
Michael HoelscherDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany.
Riccardo GavioliDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Elmar SaathoffDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany.
Christof GeldmacherDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany.
Ludwig-Maximilians-Universität München · DENational Institute for Medical Research · TZGerman Center for Infection Research · DEIstituto Superiore di Sanità · ITUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe presence of IgG and IgM against Tat, an HIV protein important for viral replication and immune dysfunction, is associated with slow disease progression in clade B HIV-infected individuals. However, although Tat activities strictly depend on the viral clade, our knowledge about the importance of anti-Tat antibodies in non-clade B HIV infection is poor. The objective of this study was to investigate the association of different anti-Tat antibody isotypes with disease progression in non-clade B HIV-infected subjects and to study the relationship between anti-Tat humoral responses and immunological abnormalities.

methodsAnti-clade B and -clade C Tat IgG, IgM and IgA titers were assessed in serum samples from 96 cART-naïve subjects with chronic HIV infection from Mbeya, Tanzania, and associated with CD4(+) T cell count, plasma viremia and CD4(+) and CD8(+) T cell phenotypes.

resultsAnti-Tat IgM were preferentially detected in chronic HIV-infected subjects with low T cell activation (p-value = 0.03) and correlated with higher CD4(+) T cell counts and lower viral loads irrespective of the duration of infection (p-value = 0.019 and p-value = 0.037 respectively). Conversely, anti-Tat IgA were preferentially detected in individuals with low CD4(+) T cell counts and high viral load (p-value = 0.02 and p-value < 0.001 respectively). The simultaneous presence of anti-Tat IgG and IgM protected from fast CD4(+) T cell decline (p-value < 0.01) and accumulation of CD38(+)HLADR(+)CD8(+) T cells (p- value = 0.029).

conclusionsAnti-Tat IgG alone are not protective in non-clade B infected subjects, unless concomitant with IgM, suggesting a protective role of persistent anti-Tat IgM irrespective of the infecting clade.

Indexed as

AdultCD8-Positive T-LymphocytesCohort StudiesDisease ProgressionFemaleHIV-1HIV AntibodiesHIV InfectionsHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MLymphocyte ActivationMaleTanzaniatat Gene Products, Human Immunodeficiency VirusHIV AntibodiesImmunoglobulin AImmunoglobulin GImmunoglobulin Mtat Gene Products, Human Immunodeficiency VirusAntibodiesClade B HIVClade C HIVDiseases progressionImmune activationTat

Identifiers

PMID27450538
PMCPMC4957276
OpenAlexW2486489962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.